{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:32:55Z","timestamp":1790274775057,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.cct.2019.105835","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T02:21:03Z","timestamp":1566440463000},"page":"105835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3)"],"prefix":"10.1016","volume":"85","author":[{"given":"Matthew M.","family":"Heeney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel R.","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Amilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Githanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baba","family":"Inusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Leonsson-Zachrisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Michelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders R.","family":"Berggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cct.2019.105835_bb0005","first-page":"101","article-title":"Pathophysiology and perioperative management of sickle cell disease","volume":"25","author":"Paradowski","year":"2015","journal-title":"J. Perioper. Pract."},{"key":"10.1016\/j.cct.2019.105835_bb0010","series-title":"GeneReviews\u00ae","article-title":"Sickle cell disease","author":"Bender","year":"2003"},{"issue":"9757","key":"10.1016\/j.cct.2019.105835_bb0015","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cct.2019.105835_bb0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.13348","article-title":"Guideline on the management of acute chest syndrome in sickle cell disease","volume":"169","author":"Howard","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.cct.2019.105835_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029786","article-title":"Association of coagulation activation with clinical complications in sickle cell disease","volume":"7","author":"Ataga","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cct.2019.105835_bb0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cct.2019.105835_bb0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.trsl.2015.07.001","article-title":"Inflammatory targets of therapy in sickle cell disease","volume":"167","author":"Owusu-Ansah","year":"2016","journal-title":"Transl. Res."},{"issue":"7","key":"10.1016\/j.cct.2019.105835_bb0055","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/jth.13717","article-title":"Prothrombotic aspects of sickle cell disease","volume":"15","author":"Sparkenbaugh","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.cct.2019.105835_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17474086.2018.1407240","article-title":"Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease","volume":"11","author":"Ansari","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.cct.2019.105835_bb0065","author":"U.S. Food & Drug Adminstration"},{"key":"10.1016\/j.cct.2019.105835_bb0070","author":"European Medicines Agency"},{"issue":"4","key":"10.1016\/j.cct.2019.105835_bb0075","article-title":"Hydroxyurea (hydroxycarbamide) for sickle cell disease","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.cct.2019.105835_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/09537104.2013.770136","article-title":"Platelet activation and inhibition in sickle cell disease (PAINS) study","volume":"25","author":"Frelinger","year":"2014","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.cct.2019.105835_bb0085","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2141.2000.02353.x","article-title":"Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia","volume":"111","author":"Inwald","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.cct.2019.105835_bb0090","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","article-title":"Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin","volume":"110","author":"Villagra","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cct.2019.105835_bb0095","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3109\/09537104.2014.940887","article-title":"The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease","volume":"26","author":"Jakubowski","year":"2015","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.cct.2019.105835_bb0100","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.thromres.2013.12.008","article-title":"A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation","volume":"133","author":"Jakubowski","year":"2014","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.cct.2019.105835_bb0105","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/bcp.12042","article-title":"A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity","volume":"75","author":"Jakubowski","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cct.2019.105835_bb0110","first-page":"199","article-title":"Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises","volume":"15","author":"Cabannes","year":"1984","journal-title":"Agents Actions Suppl."},{"issue":"5","key":"10.1016\/j.cct.2019.105835_bb0115","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0022-3476(83)80258-3","article-title":"Trial of low doses of aspirin as prophylaxis in sickle cell disease","volume":"102","author":"Greenberg","year":"1983","journal-title":"J. Pediatr."},{"issue":"7","key":"10.1016\/j.cct.2019.105835_bb0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A multinational trial of prasugrel for sickle cell vaso-occlusive events","volume":"374","author":"Heeney","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cct.2019.105835_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","article-title":"Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist","volume":"27","author":"Husted","year":"2009","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.cct.2019.105835_bb0130","author":"U.S. Food & Drug Adminstration"},{"issue":"10","key":"10.1016\/j.cct.2019.105835_bb0135","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","article-title":"Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism","volume":"11","author":"Nylander","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.cct.2019.105835_bb0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cct.2019.105835_bb0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCINTERVENTIONS.113.000293","article-title":"Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study","volume":"6","author":"Alexopoulos","year":"2013","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"7","key":"10.1016\/j.cct.2019.105835_bb0150","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacc.2012.11.032","article-title":"Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans","volume":"61","author":"Wittfeldt","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.cct.2019.105835_bb0155","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cct.2019.105835_bb0160","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/ATVBAHA.110.210732","article-title":"Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima","volume":"30","author":"Patil","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.cct.2019.105835_bb0165","first-page":"4064","article-title":"Effects of oral ticagrelor or clopidogrel before emergent PCI on the inflammatory mediators and endotheliocyte functions in STEMI patients","volume":"11","author":"Yao","year":"2018","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"45","key":"10.1016\/j.cct.2019.105835_bb0170","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1093\/eurheartj\/ehv326","article-title":"Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome","volume":"36","author":"Bernlochner","year":"2015","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.cct.2019.105835_bb0175","first-page":"147","article-title":"Vascular nitric oxide: formation and function","volume":"2010","author":"Jin","year":"2010","journal-title":"J. Blood Med."},{"key":"10.1016\/j.cct.2019.105835_bb0180","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.redox.2017.05.006","article-title":"Potential therapeutic action of nitrite in sickle cell disease","volume":"12","author":"Wajih","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.cct.2019.105835_bb0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fphys.2018.00337","article-title":"Ticagrelor improves endothelial function by decreasing circulating epidermal growth factor (EGF)","volume":"9","author":"Vieceli Dalla Sega","year":"2018","journal-title":"Front. Physiol."},{"issue":"22","key":"10.1016\/j.cct.2019.105835_bb0190","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.116.024014","article-title":"Protective effects of ticagrelor on myocardial injury after infarction","volume":"134","author":"Vilahur","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.cct.2019.105835_bb0195","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/ATVBAHA.114.304002","article-title":"Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect","volume":"34","author":"Nanhwan","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.cct.2019.105835_bb0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hoc.2013.11.003","article-title":"The role of adenosine signaling in sickle cell therapeutics","volume":"28","author":"Field","year":"2014","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"20","key":"10.1016\/j.cct.2019.105835_bb0205","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","article-title":"Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease [published correction appears in Blood Adv 2017;1(23):2058]","volume":"1","author":"Field","year":"2017","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.cct.2019.105835_bb0210","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","article-title":"Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model","volume":"35","author":"Thomas","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.cct.2019.105835_bb0215","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/ajh.25273","article-title":"A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: a 2-part phase 2 study","volume":"93","author":"Hsu","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.cct.2019.105835_bb0220","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bjh.15646","article-title":"Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study","volume":"184","author":"Kanter","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.cct.2019.105835_bb0225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4037\/ajcc2010624","article-title":"Reliability and validity of the face, legs, activity, cry, consolability behavioral tool in assessing acute pain in critically ill patients","volume":"19","author":"Voepel-Lewis","year":"2010","journal-title":"Am. J. Crit. Care"},{"issue":"2","key":"10.1016\/j.cct.2019.105835_bb0230","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3959(01)00314-1","article-title":"The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement","volume":"93","author":"Hicks","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.cct.2019.105835_bb0235","author":"PedsQL\u2122"},{"issue":"8","key":"10.1016\/j.cct.2019.105835_bb0240","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/pbc.24491","article-title":"PedsQLTM sickle cell disease module: feasibility, reliability, and validity","volume":"60","author":"Panepinto","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.cct.2019.105835_bb0245","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pbc.24776","article-title":"PedsQLTM Multidimensional Fatigue Scale in sickle cell disease: feasibility, reliability, and validity","volume":"61","author":"Panepinto","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.cct.2019.105835_bb0250","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jpeds.2008.06.030","article-title":"Medicines for children: a matter of taste","volume":"153","author":"Davies","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cct.2019.105835_bb0255","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/j.1538-7836.2011.04433.x","article-title":"Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children","volume":"9","author":"Mitchell","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.cct.2019.105835_bb0260","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1160\/TH16-09-0731","article-title":"Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia","volume":"117","author":"Jakubowski","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.cct.2019.105835_bb0265","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000207105","article-title":"Therapeutic effect of aspirin in sickle cell anaemia","volume":"66","author":"Osamo","year":"1981","journal-title":"Acta Haematol."},{"key":"10.1016\/j.cct.2019.105835_bb0270","author":"U.S. Food & Drug Adminstration"},{"issue":"6","key":"10.1016\/j.cct.2019.105835_bb0275","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s12098-011-0682-8","article-title":"Neonatal screening of sickle cell anemia: a preliminary report","volume":"79","author":"Panigrahi","year":"2012","journal-title":"Ind. J. Pediatr."},{"issue":"4","key":"10.1016\/j.cct.2019.105835_bb0280","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/03630269.2012.691434","article-title":"Newborn screening shows a high incidence of sickle cell anemia in Central India","volume":"36","author":"Jain","year":"2012","journal-title":"Hemoglobin"},{"issue":"1","key":"10.1016\/j.cct.2019.105835_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147081","article-title":"Neonatal screening and the clinical outcome in children with sickle cell disease in Central India","volume":"11","author":"Upadhye","year":"2016","journal-title":"PLoS One"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714419305506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714419305506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:46:12Z","timestamp":1761554772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714419305506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":54,"alternative-id":["S1551714419305506"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2019.105835","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3)","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2019.105835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105835"}}